Chelsea Therapeutics Announces Submission of Additional Information for NORTHERA(TM) (Droxidopa) NDA

Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP ) today announced that it has submitted additional information to the U.S. Food and Drug Administration (FDA) to resolve certain technical deficiencies in the Company's resubmitted New Drug Application (NDA) for NORTHERA™ (droxidopa). Pending confirmation by the FDA, the resubmission is expected to